Condition,70b Response (child),Correctness,Completeness,Conciseness & Clarity,Accuracy,Total (0-2) Conciseness removed,Total (0-3),GPT Response (child),Correctness,Completeness,Conciseness & Clarity,Accuracy,Total (0-2) Conciseness removed,Total (0-3),70b Response (adult),Correctness,Completeness,Conciseness & Clarity,Accuracy,Total (0-2) Conciseness removed,Total (0-3),GPT Response (adult),Correctness,Completeness,Conciseness & Clarity,Accuracy,Total (0-2) Conciseness removed,Total (0-3)
Autosomal dominant polycystic kidney disease,"Clinical management recommendations for a 10-year-old boy with autosomal dominant polycystic kidney disease (ADPKD) would include:

1. Monitoring of renal function, including serial measurement of serum creatinine and estimation of glomerular filtration rate (eGFR).
2. Ultrasound monitoring of kidney size and cyst number, with follow-up imaging every 6-12 months.
3. Management of hypertension, if present, with medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).
4. Evaluation for urinary tract infections (UTIs) and management with antibiotics as needed.
5. Encouragement of healthy lifestyle habits, including adequate fluid intake, normal diet, and regular exercise.
6. Genetic testing for the boy and his family members to confirm the ADPKD diagnosis and assess disease risk.
7. Specialist referrals to nephrology, urology, and genetics for further management and counseling.
8. Consideration of clinical trials or research studies for new treatments and management strategies.
9. Monitoring for complications such as kidney stones, hematuria, and urinary tract obstruction.
10. Psychosocial support and counseling for the child and family, including education about the disease and its impact on quality of life.

Medications that may be considered for this patient include:

1. ACE inhibitors (e.g., lisinopril, enalapril) or ARBs (e.g., losartan, valsartan) for hypertension.
2. Antibiotics (e.g., amoxicillin, ciprofloxacin) for UTIs.
3. Pain medication (e.g., acetaminophen, ibuprofen) as needed for kidney pain or discomfort.
4. Allopurinol for hyperuricemia and gout prevention, if necessary.

It is important to note that these recommendations are tailored to the specific needs of this patient and may require adjustments based on individual factors and disease progression. Regular follow-up with the healthcare team is crucial to ensure optimal management and outcomes.",0,1,0,0,1,1,"As a physician and medical geneticist, my clinical management recommendations for a 10-year-old boy with Autosomal dominant polycystic kidney disease would include regular monitoring of blood pressure, kidney function, and urinary tract infections. Genetic testing should also be offered to family members of the affected individual. Specialist referrals to a nephrologist and a genetic counselor should be made. Medications such as ACE inhibitors or ARBs may be used to control blood pressure and slow the progression of kidney disease. Additionally, lifestyle modifications such as a low-sodium diet and regular exercise should be recommended.",1,1,1,1,2,3,"For a 45-year-old man with autosomal dominant polycystic kidney disease (ADPKD), I would recommend the following clinical management strategies:

1. Monitoring: Regular follow-up appointments every 6-12 months to assess kidney function, blood pressure, and monitor for complications such as kidney stones, urinary tract infections, and aneurysms.
2. Medications:
a. Blood pressure control: Use ACE inhibitors or ARBs to manage hypertension, which can slow down kidney disease progression.
b. Pain management: For kidney stone pain, consider medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotics.
c. Anemia management: Use iron supplements or erythropoietin stimulating agents to manage anemia, which can improve fatigue and quality of life.
3. Genetic testing: Offer genetic testing to identify potential disease-causing mutations in the PKD1 or PKD2 genes. This can help family members determine their risk of inheriting the disease.
4. Specialist referrals:
a. Nephrology: Refer the patient to a nephrologist for specialized care in managing kidney disease, including dialysis or transplantation if needed.
b. Urology: Refer the patient to a urologist for management of urinary tract infections, kidney stones, or other urological complications.
c. Cardiology: Refer the patient to a cardiologist for management of hypertension and cardiovascular risk factors.
5. Lifestyle modifications: Encourage the patient to adopt healthy lifestyle habits, such as a balanced diet, regular exercise, smoking cessation, and stress management techniques.
6. Patient education: Provide the patient with educational resources and support to help them understand their condition, its management, and the impact on their quality of life.
7. Follow-up imaging: Perform serial imaging studies (e.g., ultrasound, CT scans) to monitor kidney size and cyst progression, and to detect complications early.

It's essential to individualize the management plan for each patient, taking into account their specific needs, medical history, and family dynamics.",0,0,1,0,0,1,"For a 45-year-old man with Autosomal dominant polycystic kidney disease, I would recommend regular monitoring of blood pressure, kidney function, and cyst growth using imaging such as ultrasound or MRI. Medications such as ACE inhibitors or ARBs may be prescribed to manage blood pressure and slow the progression of kidney damage. Genetic testing may be offered to family members to determine their risk of developing the disease. Referral to a nephrologist and a genetic counselor is also recommended for ongoing management and counseling on family planning and genetic risk.",1,0,1,0,1,2
Kallmann syndrome,"Clinical management recommendations for a 10-year-old boy with Kallmann syndrome:

1. Hormone replacement therapy (HRT) with recombinant human growth hormone (rhGH) and thyroid hormone to address growth delay and hypothyroidism.
2. Genetic testing to identify the genetic cause of Kallmann syndrome, including analysis of CHD7, SF1, and other relevant genes.
3. Referral to a pediatric endocrinologist for management of growth and thyroid hormone replacement therapy.
4. Referral to a geneticist or genetic counselor for genetic testing and counseling.
5. Consideration of speech therapy and occupational therapy to address cognitive and behavioral issues.
6. Regular monitoring of height and thyroid function, as well as adverse effects of HRT.
7. Consideration of early puberty induction to promote growth and development.
8. Referral to a neurologist or developmental pediatrician for evaluation and management of any neurological or developmental issues.
9. Consideration of sleep study to rule out sleep apnea.
10. Genetic counseling for family members to discuss implications of the diagnosis and potential risks for other family members.

Medications:

1. Recombinant human growth hormone (rhGH)
2. Thyroid hormone
3. Levo-thyroxine (T4) or Liothyronine (T3)

Specialist referrals:

1. Pediatric endocrinologist
2. Geneticist or genetic counselor
3. Speech therapist
4. Occupational therapist
5. Neurologist or developmental pediatrician
6. Sleep specialist

It's important to note that management of Kallmann syndrome is individualized and may vary depending on the severity of symptoms and the presence of other health issues. These recommendations should serve as a guide, and the most appropriate course of action should be determined in consultation with a multidisciplinary team of healthcare professionals.",0,0,0,0,0,0,"For a 10 year old boy with Kallmann syndrome, the specific clinical management recommendations would include:  
   
1. Medications: Hormone replacement therapy (HRT) with testosterone or estrogen to promote pubertal development and secondary sexual characteristics.  
   
2. Genetic testing: Genetic testing to confirm the diagnosis of Kallmann syndrome and identify any associated genetic mutations.  
   
3. Specialist referrals: Referral to an endocrinologist for management of HRT and monitoring of growth and development, and referral to a reproductive endocrinologist for fertility preservation options.  
   
Additionally, the patient may benefit from psychological support and counseling to address any potential emotional or psychological concerns related to delayed puberty and fertility issues.",1,1,1,1,2,3,"Clinical Management Recommendations for a 25-year-old man with Fragile X syndrome:

1. Developmental and Behavioral Assessment:
        * Comprehensive assessment by a multidisciplinary team, including a developmental pediatrician, psychologist, occupational therapist, and speech therapist, to evaluate cognitive, social, and adaptive skills.
2. Medications:
        * Consider medication for symptoms of anxiety, hyperactivity, or mood disorders, if present.
        * Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) may be effective for anxiety and mood regulation.
        * Stimulants or atomoxetine may be beneficial for attention-deficit/hyperactivity disorder (ADHD) symptoms.
3. Genetic Testing:
        * Offer genetic testing to identify the Fragile X mutation and determine the risk of transmitting the condition to future offspring.
        * Discuss the implications of a positive test result and the option of prenatal testing for future pregnancies.
4. Specialist Referrals:
        * Developmental pediatrics for ongoing developmental and behavioral assessment and management.
        * Psychiatry for management of psychiatric symptoms and medication monitoring.
        * Occupational therapy for assistance with adaptive skills and independence.
        * Speech therapy for communication and language difficulties.
        * Genetic counseling for discussion of genetic risks and implications.
5. Family Support and Education:
        * Provide education on Fragile X syndrome, its impact on cognitive and behavioral development, and available resources.
        * Encourage family support and involvement in the individual's care and decision-making process.
6. Monitoring and Follow-up:
        * Regular follow-up appointments with the multidisciplinary team to monitor progress, adjust medications, and address emerging concerns.

It is essential to tailor the management plan to the individual's specific needs and circumstances, and to collaborate with the patient, family, and healthcare providers to ensure optimal care and support.",0,0,1,0,0,1,"For a 25 year old man with Fragile X syndrome, I would recommend genetic testing to confirm the diagnosis and identify the specific mutation. As for medications, I would consider prescribing medications for anxiety, depression, and behavior problems that may be associated with the syndrome. Referral to a specialist such as a developmental or behavioral pediatrician, psychiatrist, and/or neurologist may also be helpful in managing the individual's symptoms and providing additional support. It is important to provide ongoing follow-up care to monitor the individual's progress and address any new issues that may arise.",1,1,1,1,2,3
Beckwith-Wiedemann syndrome,"Clinical management recommendations for a 3-year-old boy with Beckwith-Wiedemann syndrome (BWS) would include:

1. Medications:
        * Propranolol to manage infantile hemangiomas (IH) and reduce the risk of complications.
        * Corticosteroids may be considered for severe IH or those that are causing significant respiratory or respiratory distress.
2. Genetic testing:
        * Confirm the diagnosis by genetic testing, specifically array-comparative genomic hybridization (aCGH) or next-generation sequencing (NGS) to identify genomic imbalances.
        * Consider genetic counseling and testing for family members to assess risk of recurrence.
3. Specialist referrals:
        * Pediatric surgery for management of any surgical issues related to IH or other congenital anomalies.
        * Ophthalmology for evaluation and management of ocular abnormalities.
        * Orthopedics for management of any musculoskeletal abnormalities.
        * Genetics for counseling and testing of family members.
4. Other recommendations:
        * Regular monitoring and follow-up with a multidisciplinary team of specialists to address any emerging issues.
        * Early intervention and therapy services to address developmental delays or learning disabilities.
        * Management of associated health problems such as hypoglycemia, seizures, and sleep apnea.
5. Consider enrollment in clinical trials or research studies to advance understanding of BWS and improve treatment options.

It's important to note that each individual with BWS can have a unique presentation and management plan, so the above recommendations should be tailored to the child's specific needs.",1,0,0,0,1,1,"For a 3 year old boy with Beckwith-Wiedemann syndrome, clinical management recommendations include regular abdominal ultrasounds to monitor for Wilms tumor, alpha-fetoprotein (AFP) testing, and genetic testing to confirm the diagnosis. Referral to a pediatric endocrinologist for monitoring and management of hypoglycemia and macrosomia is recommended. Referral to a pediatric surgeon for evaluation of omphalocele and other abdominal wall defects should also be considered. There are no specific medications for Beckwith-Wiedemann syndrome.",0,1,1,0,1,2,"Clinical management recommendations for a 30-year-old woman with Beckwith-Wiedemann syndrome (BWS) would include:

1. Regular monitoring and follow-up with a multidisciplinary team, including a medical geneticist, endocrinologist, and oncologist.
2. Imaging studies, such as ultrasound and MRI, to monitor for tumors and organomegaly.
3. Genetic testing to confirm the diagnosis and identify potential genetic mutations.
4. Management of endocrine manifestations, such as hypoglycemia, with medications like diazoxide and glucagon.
5. Surveillance for cancer, including regular cancer screening and monitoring for signs of malignancy.
6. Referral to specialists, such as a pediatrician, gastroenterologist, and ophthalmologist, as needed.
7. Counseling and support for the patient and family regarding the diagnosis, management, and potential complications of BWS.
8. Consideration of clinical trials or research studies for new treatments and management strategies.
9. Regular updates and follow-up to adjust management plan as needed.

Medications that may be used to manage BWS include:

1. Diazoxide: to manage hypoglycemia
2. Glucagon: to manage hypoglycemia
3. Growth hormone: to manage growth retardation
4. Thyroid hormone: to manage hypothyroidism
5. Anti-cancer therapy: to treat cancerous tumors

It is important to note that the management of BWS is highly individualized and depends on the specific symptoms and characteristics of each patient. The recommendations provided above are general guidelines and may need to be tailored to the individual patient's needs.",0,0,0,0,0,0,"As a physician and medical geneticist, I would recommend the following clinical management for a 30-year-old woman with Beckwith-Wiedemann syndrome:  
   
1. Regular monitoring for tumor development, especially of the kidneys and liver.  
   
2. Genetic testing for the specific gene mutation causing Beckwith-Wiedemann syndrome.  
   
3. Referral to a specialist in genetics, oncology, and gastroenterology.  
   
4. Medications to manage symptoms and associated conditions, such as insulin resistance and hypoglycemia.  
   
5. Regular screening for developmental delays and speech and language disorders.  
   
6. Counseling for family planning and genetic testing for future pregnancies.  
   
7. Referral to a support group for individuals with Beckwith-Wiedemann syndrome and their families.",1,0,1,0,1,2
Glycogen storage disease due to acid maltase deficiency,"Clinical management recommendations for a 3-year-old boy with glycogen storage disease due to acid maltase deficiency would include:

1. Dietary management: A high-carbohydrate diet with frequent feedings to prevent fasting and maintain blood sugar levels. Uncooked cornstarch (Cornstarch-H) can be added to the diet to help maintain blood sugar levels.
2. Enzyme replacement therapy: Acid maltase enzyme replacement therapy (rh-AMG) is available and can help improve muscle strength and endurance, reduce muscle pain, and improve lung function.
3. Medications:
        * Muscle weakness: cortef (hydrocortisone) or prednisone to reduce muscle weakness
        * Muscle pain: acetaminophen or ibuprofen as needed
        * Respiratory symptoms: albuterol inhaler as needed for wheezing or shortness of breath
4. Genetic testing: Genetic testing for the GAA gene to confirm the diagnosis and carrier status of family members.
5. Specialist referrals:
        * Geneticist for genetic counseling and testing
        * Metabolic specialist for dietary management and monitoring
        * Pulmonologist for lung function assessment and management
        * Physical therapist for muscle strength and endurance exercises
        * Occupational therapist for assistance with daily living activities
6. Regular monitoring:
        * Regular blood tests to monitor blood sugar levels, liver function, and other metabolic markers
        * Regular assessment of muscle strength and function
        * Monitoring for any respiratory symptoms
7. Educational support: Provide educational resources and support to the family to help them understand and manage the child's condition.

It is important to note that the best management plan for this patient will depend on the specifics of the case, and the recommendations above should be tailored to the individual patient's needs and circumstances.",0,0,1,0,0,1,"For a 3 year old boy with Glycogen storage disease due to acid maltase deficiency, the specific clinical management recommendations would include:  
   
1. Medications: Enzyme replacement therapy with alglucosidase alfa (Lumizyme) is the mainstay of treatment. It can improve muscle strength and function and prolong survival.  
   
2. Genetic testing: Genetic testing should be performed to confirm the diagnosis and identify the specific mutation. This can help with prognosis and family planning.  
   
3. Specialist referrals: Referral to a pediatric endocrinologist, neurologist, and nutritionist should be considered. Physical therapy and occupational therapy may also be helpful.  
   
Overall, management of glycogen storage disease due to acid maltase deficiency requires a multidisciplinary approach to optimize outcomes and quality of life.",1,0,1,0,1,2,"Clinical management recommendations for a 35-year-old woman with Prader-Willi syndrome (PWS) would include:

1. Medications:
        * Growth hormone replacement therapy (GHRT) to address growth hormone deficiency and improve body composition.
        * Appetite-suppressing medications, such as metformin or topiramate, to help manage hyperphagia and weight gain.
        * Behavioral interventions, such as cognitive-behavioral therapy (CBT), to address any associated psychological or behavioral issues.
2. Genetic testing:
        * Confirm the diagnosis of PWS by genetic testing, which can identify the presence of a deletion or uniparental disomy (UPD) of chromosome 15q11.2-q13.
        * Consider genetic counseling for the patient and her family to discuss implications of the diagnosis and potential risks for future children.
3. Specialist referrals:
        * Endocrinologist for management of growth hormone deficiency and metabolic issues.
        * Psychiatrist or psychologist for management of behavioral and psychological issues.
        * Nutritionist or dietician for guidance on healthy eating habits and weight management.
        * Physical therapist for exercise and mobility support.
        * Social worker or case manager for assistance with accessing resources and support services.
4. Monitoring and follow-up:
        * Regular follow-up appointments with the primary care physician and specialists to monitor the patient's overall health and response to treatment.
        * Annual assessments of growth and development, including measurement of height and weight, and monitoring of body mass index (BMI).
        * Periodic assessments of cognitive and behavioral function, including evaluation of any changes in mood, behavior, or cognitive abilities.

It's important to note that management of PWS is multidisciplinary and requires a collaborative approach between various healthcare providers, the patient, and her family.",1,0,0,0,1,1,"For a 35-year-old woman with Prader-Willi syndrome, my specific clinical management recommendations would include regular monitoring of her weight and diet, with the goal of maintaining a healthy BMI. Medications such as growth hormone therapy and appetite suppressants may also be considered. Genetic testing may be recommended to confirm the diagnosis and identify any potential genetic variations or mutations. Referrals to specialists such as endocrinologists, dietitians, and mental health professionals may also be necessary to provide comprehensive care and support for the patient.",1,0,1,0,1,2
Multiple endocrine neoplasia type 2,"For a 7-year-old boy with Multiple Endocrine Neoplasia Type 2 (MEN2), I would recommend the following clinical management plan:

1. Medications:
        * Thyroid hormone replacement therapy (T4 or T3) to manage hypothyroidism.
        * Propranolol to manage hyperthyroidism symptoms.
        * Octreotide to manage growth hormone excess.
2. Genetic testing:
        * Perform genetic testing to identify the presence of the RET proto-oncogene mutation, which is the genetic hallmark of MEN2.
        * Offer genetic counseling to the family to discuss the implications of the diagnosis and the potential for other family members to be affected.
3. Specialist referrals:
        * Endocrinologist to manage thyroid and growth hormone disorders.
        * Surgeon to consider surgical intervention for thyroid nodules or other endocrine tumors.
        * Radiologist to monitor for any radiological signs of tumors.
        * Geneticist to provide genetic counseling and support.
4. Follow-up:
        * Regular follow-up appointments with the endocrinologist to monitor thyroid function, growth hormone levels, and any signs of tumor progression.
        * Regular thyroid ultrasound and other imaging studies to monitor for any changes in thyroid nodules or other endocrine tumors.
        * Monitor for any signs of other endocrine disorders, such as hypocalemia (low calcium levels) or hyperparathyroidism.

It's important to note that the management of MEN2 requires a multidisciplinary approach, involving a team of specialists who can provide comprehensive care and support to the patient and their family.",0,0,1,0,0,1,"For a 7-year-old boy with Multiple endocrine neoplasia type 2, the specific clinical management recommendations would be:  
   
1. Genetic testing: Confirm the diagnosis of MEN2 by genetic testing of the RET gene.  
   
2. Specialist referrals: Refer the patient to an endocrinologist, surgeon, and genetic counselor.  
   
3. Medications: Administer prophylactic thyroidectomy to prevent medullary thyroid carcinoma.   
  
4. Screening: Regular monitoring with serum calcitonin levels and imaging to detect recurrent or metastatic disease.  
   
5. Counseling: Provide genetic counseling to the patient and their family members to identify potential carriers of the RET mutation.  
   
6. Follow-up: Ensure regular follow-up appointments with the patient and their healthcare team to monitor their condition and adjust treatment as needed.",1,1,1,1,2,3,"For a 35-year-old man with glycogen storage disease due to acid maltase deficiency, I would recommend the following clinical management plan:

1. Medications:
        * Enzyme replacement therapy (ERT) with acid maltase enzyme infusions to replace the deficient enzyme and improve glycogen metabolism.
        * Chaperone therapy with drugs like velaglucerase to enhance the activity of residual acid maltase enzyme.
        * Symptomatic management of muscle weakness, fatigue, and cramps with medications like baclofen, tizanidine, and dantrolene.
2. Genetic testing:
        * Perform genetic testing to identify the specific genetic mutations causing the acid maltase deficiency.
        * Offer genetic counseling to the patient and his family to discuss the implications of the diagnosis and potential risks to family members.
3. Specialist referrals:
        * Refer the patient to a specialized multidisciplinary team including a metabolic geneticist, neurologist, physical therapist, and dietician for comprehensive management and monitoring.
        * Collaborate with specialists in endocrinology and metabolism to manage associated metabolic complications.
4. Dietary management:
        * Advise a high-carbohydrate diet with frequent feedings to maintain blood glucose levels and reduce the risk of hypoglycemia.
        * Encourage adequate hydration and provide guidelines for emergency protocols in case of metabolic decompensation.
5. Monitoring:
        * Regular follow-up appointments with the multidisciplinary team to monitor disease progression, adjust medications, and address emerging complications.
        * Laboratory tests to monitor liver and muscle glycogen levels, creatine kinase, and other markers of disease activity.
6. Supportive care:
        * Physical therapy to maintain muscle strength and prevent muscle atrophy.
        * Occupational therapy to optimize daily functioning and independence.
        * Psychological counseling to address potential emotional and psychosocial impacts of the disease.
7. Family planning:
        * Offer genetic counseling and testing for family members, particularly if they are considering children.
        * Discuss the risks and benefits of reproductive options, such as preimplantation genetic diagnosis or prenatal testing, if desired.
8. Emergency care:
        * Establish a crisis management plan for metabolic decompensation, including emergency protocols for hydration, glucose supplementation, and hospitalization.
        * Provide education and support for the patient and family to recognize and respond to emergency situations promptly.

This comprehensive management plan aims to address the complex clinical and metabolic needs of a patient with glycogen storage disease due to acid maltase deficiency, improve quality of life, and prevent or minimize complications associated with the disorder.",0,0,0,0,0,0,"As a physician and medical geneticist, my specific clinical management recommendations for a 35-year-old man with Glycogen storage disease due to acid maltase deficiency would include:  
   
1. Medications: Enzyme replacement therapy with alglucosidase alfa is recommended to improve muscle strength and respiratory function.  
   
2. Genetic testing: Genetic testing is recommended for the patient and his family members to determine the specific genetic mutation causing the disease and identify carriers.  
   
3. Specialist referrals: Referral to a neuromuscular specialist, pulmonologist, and nutritionist is recommended to manage and monitor the disease's complications, including respiratory failure, cardiac dysfunction, and nutritional deficiencies.  
   
4. Regular monitoring: Regular monitoring of the patient's muscle strength, respiratory function, cardiac function, and nutritional status is necessary to detect and manage disease complications promptly.  
   
5. Lifestyle modifications: Exercise should be encouraged, but the patient should avoid strenuous activities that could lead to muscle damage and increase the risk of rhabdomyolysis.  
   
Overall, the management of Glycogen storage disease due to acid maltase deficiency requires a multidisciplinary approach to optimize patient outcomes.",1,1,1,1,2,3
Full NF2-related schwannomatosis,"Clinical management recommendations for a 10-year-old boy with full NF2-related schwannomatosis would include:

1. Annual monitoring of tumor growth and symptoms by a multidisciplinary team of specialists, including a neurologist, neurosurgeon, ophthalmologist, and geneticist.
2. Regular imaging studies (MRI) to assess tumor growth and progression.
3. Management of symptoms such as pain, seizures, and hydrocephalus with appropriate medications and interventions.
4. Genetic testing to confirm the diagnosis and identify potential genetic mutations.
5. Referral to a specialized NF2 clinic or center for comprehensive care and management.
6. Consideration of chemotherapy or other treatments to slow tumor growth, particularly if the patient is experiencing rapid progression of symptoms.
7. Close monitoring of hearing and vision to address any issues promptly.
8. Psychosocial support and counseling for the patient and family to address the emotional and psychological impact of the condition.
9. Regular follow-up appointments with the multidisciplinary team to adjust management strategies as needed.

Medications that may be used to manage symptoms include:

1. Pain medications such as gabapentin or pregabalin for pain management.
2. Anti-seizure medications such as levetiracetam or valproate for seizure control.
3. Shunt surgery may be necessary to manage hydrocephalus.

It is important to note that the management of NF2-related schwannomatosis is complex and may vary depending on the individual patient's needs and specific symptoms. Therefore, it is essential to work closely with a multidisciplinary team of specialists to ensure comprehensive and coordinated care.",1,0,0,0,1,1,"""As a physician and medical geneticist, my specific clinical management recommendations for a 10 year old boy with Full NF2-related schwannomatosis would include:  
   
1. Regular monitoring with MRI scans to assess the growth and spread of schwannomas.  
   
2. Consideration of surgical intervention for symptomatic schwannomas.  
   
3. Referral to a neurologist or neurosurgeon with expertise in NF2-related schwannomatosis.  
   
4. Genetic counseling and testing for the patient and his family members to determine the underlying genetic mutation and assess the risk for other family members.  
   
5. Consideration of medications such as bevacizumab or everolimus to slow the growth of schwannomas.  
   
Overall, a multidisciplinary team approach involving neurology, neurosurgery, and genetics is crucial for the management of Full NF2-related schwannomatosis in a 10 year old boy.""",1,1,1,1,2,3,"Clinical management recommendations for a 35-year-old woman with Orofaciodigital syndrome type 1 (OFD1) would include:

1. Genetic testing: OFD1 is caused by mutations in the OFD1 gene. Genetic testing can confirm the diagnosis and identify the specific mutation.
2. Multidisciplinary care: Referral to a multidisciplinary team including medical geneticists, neurologists, ophthalmologists, orthodontists, and speech therapists to address the various symptoms and prevent complications.
3. Neurological management:
        * Seizure management: Anticonvulsants such as valproic acid or levetiracetam may be prescribed to control seizures.
        * Muscle weakness management: Physical therapy and occupational therapy to maintain muscle strength and function.
        * Sleep management: Sleep studies to diagnose and manage sleep disorders, such as sleep apnea.
4. Ophthalmic management:
        * Eye exams: Regular eye exams to monitor for vision loss, cataracts, and other eye complications.
        * Glasses or contact lenses: Prescription of corrective lenses to improve vision.
        * Surgery: Consideration of surgical interventions, such as cataract surgery, if necessary.
5. Orthodontic management:
        * Dental exams: Regular dental exams to monitor for dental problems, such as tooth crowding or malocclusion.
        * Orthodontic treatment: Orthodontic treatment, such as braces or aligners, to improve dental alignment and function.
6. Speech and language therapy:
        * Evaluation: Speech and language evaluation to assess communication skills and identify areas for improvement.
        * Therapy: Speech and language therapy to improve communication skills, such as articulation, fluency, and comprehension.
7. Management of other symptoms:
        * Physical therapy: Physical therapy to improve mobility, balance, and coordination.
        * Occupational therapy: Occupational therapy to improve daily functioning and independence.
        * Psychological support: Psychological support and counseling to address any emotional or psychological challenges.
8. Genetic counseling: Genetic counseling to discuss the risks and implications of the syndrome, as well as reproductive options.
9. Follow-up: Regular follow-up appointments with the multidisciplinary team to monitor the patient's condition and adjust management plans as needed.

Medications that may be prescribed include anticonvulsants, muscle relaxants, and sleep aids, as well as medications to manage other symptoms such as anxiety or depression. The specific medications and dosages will depend on the individual patient's needs and medical history.",1,0,0,0,1,1,"As a physician and medical geneticist, I would recommend the following clinical management for a 35-year-old woman with Orofaciodigital syndrome type 1:  
   
1. Medications: There are no specific medications for this condition. Treatment is usually symptomatic and supportive.  
   
2. Genetic testing: I would recommend genetic testing to confirm the diagnosis and identify any potential genetic mutations. This can help with family planning and genetic counseling.  
   
3. Specialist referrals: Referrals to a neurologist, ophthalmologist, and/or orthopedic surgeon may be necessary to manage any associated neurological, visual, or skeletal abnormalities.  
   
4. Regular follow-up: Regular follow-up appointments with a healthcare provider, such as a primary care physician or medical geneticist, are important to monitor for any potential complications and to ensure appropriate management of the condition.",1,0,1,0,1,2
Glutaryl-CoA dehydrogenase deficiency,"Clinical management recommendations for a 3-month-old boy with Glutaryl-CoA dehydrogenase deficiency:

1. Immediate treatment:
a. Initiate a ketogenic diet, which restricts glutaryl-CoA production and reduces the risk of neurological damage.
b. Provide appropriate hydration and electrolyte supplementation.
c. Monitor for signs of ketosis (e.g., vomiting, seizures) and adjust dietary ratios as needed.
2. Medications:
a. Consider prescribing antiepileptic drugs, such as valproate or levetiracetam, to control seizures, if present.
b. Monitor for signs of neurological deterioration, and consider corticosteroids for inflammation if necessary.
3. Genetic testing:
a. Perform genetic testing to confirm the diagnosis and identify the specific genetic mutation(s) responsible for the deficiency.
b. Offer genetic counseling to the parents, discussing the implications of the diagnosis and potential risks for future children.
4. Specialist referrals:
a. Pediatric neurologist: for management of seizures, neurological assessment, and monitoring.
b. Dietician: for guidance on implementing and monitoring the ketogenic diet.
c. Geneticist: for counseling and guidance on genetic testing and implications.
d. Metabolic specialist: for management of metabolic aspects of the disorder.
5. Follow-up:
a. Regular follow-up appointments (e.g., every 3-6 months) to monitor the patient's clinical status, adjust dietary ratios, and address any concerns.
b. Monitoring of growth and development, and interventions as needed to address any delays.
6. Family education:
a. Provide education on the disorder, its management, and the importance of adhering to the ketogenic diet.
b. Discuss the potential risks and benefits of various treatments, and the importance of follow-up appointments.
7. Other considerations:
a. Consider collaborating with a multidisciplinary team, including a psychologist, social worker, and other specialists as needed.
b. Address any psychosocial or cultural factors that may impact the patient's management and outcomes.

Please note that these recommendations are general and may need to be tailored to the individual patient's needs and circumstances.",0,0,0,0,0,0,"As a physician and medical geneticist, I would recommend the following clinical management for a 3-month-old boy with Glutaryl-CoA dehydrogenase deficiency:  
   
1. Start the patient on a low lysine diet immediately to prevent the accumulation of toxic metabolites.   
  
2. Prescribe carnitine supplements to help excrete the toxic metabolites.   
  
3. Initiate treatment with antibiotics in case of an infection to prevent metabolic decompensation.   
  
4. Conduct genetic testing to confirm the diagnosis and identify any other genetic mutations or conditions.   
  
5. Refer the patient to a metabolic specialist for ongoing monitoring and management of the condition.   
  
6. Provide genetic counseling to the family to explain the inheritance pattern and the risk of recurrence in future pregnancies.   
  
7. Educate the family on the importance of routine follow-up visits and emergency management plans in case of metabolic decompensation.",1,1,1,1,2,3,"Clinical management recommendations for a 35 year old woman with Glutaryl-CoA dehydrogenase deficiency:

1. Medications:
        * Prescribe a high-fat, low-carbohydrate diet to reduce the risk of metabolic crises.
        * Consider sodium benzoate (500-1000 mg/day) to reduce glutaric acid production.
        * Monitor and treat seizures, if present, with appropriate anticonvulsant medications.
2. Genetic testing:
        * Offer genetic testing to identify the genetic mutations causing the deficiency.
        * Perform genetic counseling to discuss the implications of the test results and potential risks for family members.
3. Specialist referrals:
        * Refer to a metabolic specialist or geneticist for further management and monitoring.
        * Consider referral to a neurologist for management of seizures, if present.
        * Refer to a dietician for dietary counseling and monitoring.
4. Monitoring:
        * Regularly monitor plasma glutaric acid and urinary glutaric acid levels to assess disease severity and response to treatment.
        * Monitor for signs of metabolic crises, such as lethargy, vomiting, seizures, and respiratory distress.
5. Follow-up:
        * Schedule regular follow-up appointments to monitor disease progression and adjust treatment as needed.
        * Encourage family planning and reproductive counseling to discuss potential risks and options for future pregnancies.
6. Patient education:
        * Provide education on the disease, its management, and the importance of dietary compliance.
        * Discuss the potential risks and benefits of various treatments and the importance of follow-up appointments.
7. Support and resources:
        * Offer support and resources for the patient and her family, such as genetic counseling, support groups, and patient advocacy organizations.",0,0,0,0,0,0,"As a physician and medical geneticist, I would recommend the following clinical management for a 35-year-old woman with Glutaryl-CoA dehydrogenase deficiency:  
   
1. Medications: I would prescribe a low-lysine diet and carnitine supplementation to manage symptoms and prevent metabolic crises.  
   
2. Genetic testing: I would recommend genetic testing for the patient and her family members to identify any carriers or affected individuals.  
   
3. Specialist referrals: I would refer the patient to a metabolic specialist, a nutritionist/dietician, and a genetic counselor for ongoing management and support.  
   
Overall, careful monitoring, early intervention, and ongoing management are essential for individuals with Glutaryl-CoA dehydrogenase deficiency to prevent metabolic crises and improve long-term outcomes.",1,1,1,1,2,3
Maple syrup urine disease,"Clinical management recommendations for a 10-day-old boy with Maple syrup urine disease (MSUD):

1. Immediately start treatment with intravenous glucose and insulin to prevent ketosis and hypoglycemia.
2. Administer nitrogen-scavenging compounds, such as sodium phenylbutyrate, to reduce ammonia production.
3. Initiate a low-protein, high-calorie diet to minimize ammonia production and promote growth.
4. Refer to a metabolic geneticist or a specialized MSUD center for further management and genetic counseling.
5. Perform genetic testing to confirm the diagnosis and identify the specific genetic mutations.
6. Consider liver transplantation as a long-term option, as it can correct the underlying metabolic defect.
7. Collaborate with a multidisciplinary team, including a dietitian, neonatologist, and social worker, to provide comprehensive care and support.
8. Monitor blood ammonia levels, electrolytes, and glucose frequently to adjust treatment as needed.
9. Consider using alternative therapies, such as sodium benzoate or ravicti, which can help reduce ammonia production.
10. Educate parents and caregivers on the management of MSUD and the importance of strict adherence to the treatment plan.

It is important to note that MSUD is a complex and rare disorder, and management should be individualized based on the patient's specific needs and genetic mutations. A multidisciplinary team of specialists with experience in MSUD management should be involved in the patient's care to ensure optimal outcomes.",0,0,1,0,0,1,"As a physician and medical geneticist, I would recommend the following clinical management recommendations for a 10 day old boy with Maple syrup urine disease:  
   
1. Initiate emergency treatment with a low-protein diet, intravenous fluids, and IV administration of thiamine, carnitine, and glucose.  
   
2. Genetic testing should be performed to confirm the diagnosis and identify the specific genetic mutation responsible for the disease.  
   
3. Referral to a metabolic specialist or a metabolic clinic should be made for ongoing management and monitoring of the patient's condition.  
   
4. Long-term management should include a strict low-protein diet, regular blood monitoring, and medication (such as thiamine, carnitine, and biotin supplements) as prescribed by the metabolic specialist.  
   
5. Genetic counseling should be offered to the patient's family to discuss the risk of recurrence in future pregnancies and the importance of carrier testing for family members.",1,0,1,0,1,2,"Clinical Management Recommendations:

1. Hormone replacement therapy (HRT): Prescribe a combination of glucocorticoids (e.g., hydrocortisone) and mineralocorticoids (e.g., fludrocortisone) to replace the deficient hormones.
2. Adrenal crisis prevention: Educate the patient about the signs and symptoms of adrenal crisis (e.g., vomiting, abdominal pain, hypotension) and the need for prompt medical attention if they occur. Encourage her to wear a medical alert bracelet.
3. Genetic testing: Offer genetic testing to identify the specific genetic mutation causing the cytochrome P450 oxidoreductase deficiency. This information can help family planning and reproductive counseling.
4. Specialist referrals:
a. Endocrinologist: For ongoing management of hormone replacement therapy and monitoring of hormone levels.
b. Geneticist: For genetic counseling and testing, and to discuss family planning options.
c. OB-GYN: For reproductive health care and management of any menstrual irregularities.
5. Monitoring: Regularly monitor the patient's hormone levels, blood pressure, and electrolyte balance to ensure optimal replacement therapy and prevent adrenal crisis.
6. Education: Provide education on the condition, its management, and the importance of adherence to medication and follow-up appointments.
7. Follow-up: Schedule regular follow-up appointments (e.g., every 3-6 months) to monitor medication effectiveness, adjust dosages as needed, and address any concerns or adverse effects.

Medications:

1. Hydrocortisone (glucocorticoid)
2. Fludrocortisone (mineralocorticoid)

Genetic Testing:

1. Cytochrome P450 oxidoreductase deficiency gene testing (e.g., CYP21A2, CYP11A1, or CYP17A1)

Specialist Referrals:

1. Endocrinologist
2. Geneticist
3. OB-GYN

It is important to note that the specific management plan may vary depending on the patient's individual needs and medical history. This plan should be tailored to the patient's unique circumstances and should be overseen by a healthcare provider with expertise in endocrinology and medical genetics.",0,1,0,0,1,1,"For a 32 year old woman with Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency, I would recommend the following clinical management:  
   
1. Medications: Glucocorticoid replacement therapy and mineralocorticoid replacement therapy to manage adrenal insufficiency and maintain electrolyte balance.  
   
2. Genetic testing: Confirmatory testing and genetic counseling to identify the specific mutation and assess the risk of passing it on to future children.  
   
3. Specialist referrals: Referral to an endocrinologist for ongoing management of hormone replacement therapy and monitoring of adrenal function. Referral to a reproductive endocrinologist for fertility counseling and management if desired.  
   
Overall, the goal of clinical management is to maintain adequate hormone levels, manage symptoms of adrenal insufficiency, and prevent long-term complications such as infertility and osteoporosis.",0,1,1,0,1,2
Chronic visceral acid sphingomyelinase deficiency,"I am not a licensed medical professional, but I can provide some general information about the clinical management of Chronic visceral acid sphingomyelinase deficiency.

A 2-year-old boy with Chronic visceral acid sphingomyelinase deficiency (CVAS) requires prompt and comprehensive clinical management to prevent complications and improve quality of life. The following are some specific clinical management recommendations:

1. Enzyme replacement therapy (ERT): This is the primary treatment for CVAS, and it involves replacing the deficient enzyme, acid sphingomyelinase, with a recombinant form. The most commonly used ERT for CVAS is called olesoxime.
2. Symptomatic management: Manage symptoms such as abdominal pain, vomiting, diarrhea, and fever with appropriate medications. For example, antiemetics, antipyretics, and pain management medications may be used as needed.
3. Dietary management: A diet low in sphingomyelin and high in fatty acids may help alleviate symptoms. Encourage the child to consume foods rich in omega-3 fatty acids, such as fish, nuts, and seeds.
4. Genetic testing: Genetic testing can help confirm the diagnosis and identify the genetic mutation responsible for the deficiency. This information can be useful for family planning and genetic counseling.
5. Specialist referrals: Given the complexity of CVAS, it is essential to involve a multidisciplinary team of specialists, including a pediatrician, gastroenterologist, geneticist, nutritionist, and social worker. Regular follow-up appointments with these specialists will help monitor the child's condition and address any emerging issues.
6. Monitoring: Regular monitoring of the child's condition is crucial to prevent complications. This includes regular blood tests to assess liver and kidney function, as well as measurement of sphingomyelin levels in the blood. Imaging studies, such as ultrasound or MRI, may also be used to monitor the progression of the disease.
7. Psychosocial support: CVAS can significantly impact the quality of life of the child and their family. It is essential to provide psychosocial support and counseling to help them cope with the diagnosis and manage the associated challenges.

Please note that these recommendations are general and may need to be tailored to the individual child's needs and circumstances. It is important to work closely with a licensed healthcare professional to ensure the child receives appropriate and timely care.",0,0,1,0,0,1,"For a 2 year old boy with Chronic visceral acid sphingomyelinase deficiency, the specific clinical management recommendations would include:  
   
1. Enzyme replacement therapy with recombinant human acid sphingomyelinase (rhASM) to reduce the accumulation of sphingomyelin in organs.  
   
2. Genetic testing for the patient and family members to identify carriers and offer genetic counseling.  
   
3. Referral to a specialist in medical genetics, metabolic disorders, and pediatrics.  
   
4. Monitoring of liver and spleen function, lung function, and bone density.  
   
5. Supportive care, including physical therapy and occupational therapy, to manage symptoms and improve quality of life.  
   
6. Regular follow-up visits with the medical team to adjust treatment and ensure optimal management of the disease.",1,1,1,1,2,3,"I am not a licensed medical professional, but I can provide some general information on the management of Chronic visceral acid sphingomyelinase deficiency.

A 35-year-old man with Chronic visceral acid sphingomyelinase deficiency (also known as Niemann-Pick disease type A/B) would require a multidisciplinary approach to management. Here are some specific clinical management recommendations:

1. Medications:
a. Enzyme replacement therapy (ERT) with rhA-SMase (recombinant human acid sphingomyelinase) is the primary treatment.
b. Osteoporosis medications, such as bisphosphonates, may be prescribed to prevent bone loss.
c. Respiratory medications, such as bronchodilators, may be used to manage respiratory symptoms.
2. Genetic testing:
a. Genetic testing is necessary to confirm the diagnosis and identify the genetic mutations responsible for the deficiency.
b. The patient and family members should undergo genetic counseling to discuss the implications of the diagnosis and the potential risks for other family members.
3. Specialist referrals:
a. The patient should be referred to a medical geneticist or a metabolic specialist for further management and monitoring.
b. The patient may also benefit from referrals to a pulmonologist, gastroenterologist, and orthopedic surgeon to manage related symptoms and complications.
4. Other management considerations:
a. Regular monitoring of liver and spleen size, lung function, and bone density is essential.
b. The patient should receive vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b to prevent infections.
c. The patient may benefit from physical therapy to maintain muscle strength and mobility.
d. Psychosocial support and counseling may be helpful in addressing the emotional and psychological impact of the disease.
5. Diet and lifestyle modifications:
a. A healthy diet rich in fruits, vegetables, and whole grains is recommended.
b. Encourage adequate hydration and a calcium-rich diet to support bone health.
c. The patient should avoid smoking and alcohol consumption.

It is essential to note that the above recommendations are general guidelines and may need to be tailored to the individual patient's needs and circumstances. A multidisciplinary team of healthcare professionals should work together to provide comprehensive care and monitor the patient's condition regularly.",0,0,1,0,0,1,"As a physician and medical geneticist, my specific clinical management recommendations for a 35-year-old man with Chronic visceral acid sphingomyelinase deficiency would be as follows:  
   
1. Medications: Enzyme replacement therapy (ERT) with recombinant human acid sphingomyelinase (rhASM) is the only approved treatment for this condition. Therefore, I would recommend initiating ERT with rhASM.  
   
2. Genetic Testing: Genetic testing should be performed to confirm the diagnosis and to identify the specific mutations responsible for the disease. This information can help in predicting the patient's prognosis and in counseling family members regarding their risk of inheriting the condition.  
   
3. Specialist Referrals: Referral to a specialist in metabolic disorders or medical genetics is recommended to ensure appropriate management of the disease. Additionally, referral to a gastroenterologist or hepatologist may be necessary for the management of liver and spleen enlargement.  
   
Overall, early diagnosis and prompt initiation of ERT are crucial for the management of Chronic visceral acid sphingomyelinase deficiency.",1,1,1,1,2,3
Emery-Dreifuss muscular dystrophy,"Certainly! Here are my specific clinical management recommendations for a 7 year old boy with Emery-Dreifuss muscular dystrophy:

1. Medications:
        * Prescribe corticosteroids (e.g., prednisone) to reduce inflammation and slow muscle degeneration.
        * Consider anticonvulsants (e.g., valproate) for seizure control, if applicable.
        * Manage pain with analgesics (e.g., acetaminophen, ibuprofen) and/or muscle relaxants (e.g., baclofen) as needed.
2. Genetic testing:
        * Offer genetic counseling and testing for the boy's parents to determine if they are carriers of the Emery-Dreifuss mutation.
        * Consider genetic testing for the boy's siblings to determine if they are also at risk of inheriting the condition.
3. Specialist referrals:
        * Refer the boy to a pediatric neurologist for management of muscle weakness, seizures, and other neurological symptoms.
        * Refer the boy to a physical therapist for exercises and stretches to maintain muscle strength and flexibility.
        * Refer the boy to an orthotist for assistance with braces or other orthotics to support weakened muscles.
        * Consider referral to a pulmonologist for management of respiratory complications, if applicable.
4. Other interventions:
        * Ensure the boy receives appropriate vaccinations, particularly against respiratory pathogens.
        * Encourage regular exercise, such as swimming or physical therapy, to maintain muscle strength and cardiovascular health.
        * Provide appropriate assistive devices, such as a wheelchair or walker, to assist with mobility as needed.
        * Consider gastrostomy tube placement for feeding difficulties, if applicable.
5. Follow-up:
        * Schedule regular follow-up appointments with the boy's primary care physician and specialists to monitor his condition and adjust management plans as needed.

Please note that these recommendations are specific to the case of a 7 year old boy with Emery-Dreifuss muscular dystrophy and may vary depending on individual patient factors and local resources. It's important to work closely with a multidisciplinary care team to ensure comprehensive and coordinated care for the patient.",0,0,1,0,0,1,"As a physician and medical geneticist, I would recommend the following clinical management for a 7 year old boy with Emery-Dreifuss muscular dystrophy:  
   
1. Medications: There is currently no cure for Emery-Dreifuss muscular dystrophy, but medications such as corticosteroids and ACE inhibitors may help manage symptoms.  
   
2. Genetic testing: Genetic testing should be performed to confirm the diagnosis and identify any specific mutations that may be present.  
   
3. Specialist referrals: The child should be referred to a neurologist, cardiologist, and physical therapist for specialized care.  
   
4. Exercise and physical therapy: Regular exercise and physical therapy can help maintain muscle strength and flexibility.  
   
5. Cardiac monitoring: Regular cardiac monitoring is important as Emery-Dreifuss muscular dystrophy can lead to heart problems.  
   
6. Genetic counseling: The family should be offered genetic counseling to discuss the risk of the condition in future pregnancies and family planning options.",1,1,1,1,2,3,"Clinical management recommendations for a 35-year-old man with Emery-Dreifuss muscular dystrophy (EDMD) would include:

1. Medications:
        * Muscle weakness: Consider prescribing corticosteroids, such as prednisone, to reduce muscle inflammation and slow disease progression.
        * Muscle spasticity: Prescribe muscle relaxants, such as baclofen or tizanidine, to manage spasticity and improve mobility.
        * Pain management: Prescribe pain relievers, such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), to manage pain associated with muscle weakness.
2. Genetic testing:
        * Offer genetic testing to confirm the diagnosis and identify the specific genetic mutation responsible for the disease.
        * Discuss the benefits and limitations of genetic testing with the patient and his family, and ensure that they understand the implications of a positive test result.
3. Specialist referrals:
        * Neurology: Refer the patient to a neurologist for further evaluation and management of muscle weakness and spasticity.
        * Physical therapy: Refer the patient to a physical therapist to develop an exercise program that maintains muscle strength and flexibility.
        * Occupational therapy: Refer the patient to an occupational therapist to assist with adaptive equipment and strategies to maintain independence in daily activities.
        * Orthotics/prosthetics: Refer the patient to an orthotist/prosthetist to discuss options for assistive devices, such as braces or splints, to support weakened muscles.
4. Follow-up:
        * Schedule regular follow-up appointments to monitor disease progression, adjust medications as needed, and address any concerns or complications that arise.
5. Family counseling:
        * Offer genetic counseling to the patient's family members to discuss the implications of the diagnosis and the potential risks to other family members.
6. Supportive care:
        * Encourage the patient to participate in support groups and counseling to address any emotional or psychological impact of the diagnosis.
7. Multidisciplinary care:
        * Collaborate with other healthcare professionals, such as respiratory and cardiology specialists, to provide comprehensive care for the patient's complex needs.

It's important to note that the clinical management of EDMD is highly individualized, and the specific recommendations may vary depending on the patient's symptoms, disease severity, and other factors.",0,0,1,0,0,1,"As a medical geneticist, I would recommend genetic testing to confirm the diagnosis of Emery-Dreifuss muscular dystrophy. I would also refer the patient to a neurologist and a physical therapist for further evaluation and management.  
   
In terms of medications, there is no specific treatment for Emery-Dreifuss muscular dystrophy, but symptomatic management may include the use of beta-blockers for cardiac arrhythmias and orthopedic interventions for joint contractures.  
   
I would also recommend genetic counseling for the patient and any family members who may be at risk of inheriting the condition.",1,0,1,0,1,2
